Phase I multiple-ascending dose (MAD) trial of ARI 3037MO

Trial Profile

Phase I multiple-ascending dose (MAD) trial of ARI 3037MO

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2012

At a glance

  • Drugs ARI 3037MO (Primary)
  • Indications Dyslipidaemias
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms MAD
  • Sponsors Arisaph Pharmaceuticals
  • Most Recent Events

    • 23 Nov 2012 New trial record
    • 07 Nov 2012 Results were presented at the American Heart Association meeting, according to an Arisaph Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top